Clinical trialNCT02987543CompletedPhase 3Interventional

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

SponsorAstraZenecaEnrollment387Metastatic Castration-resistant Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Johann de Bono, M.D., Ph.D.
The Institute of Cancer Research, United Kingdom
Principal Investigator
clinicaltrials.gov ↗
Maha Hussain, M.D., FACP, FASCO
Northwestern University, United States of America
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

204 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
La Rioja, Argentina
Research Site
Rosario, Argentina

Australia

Research Site
Adelaide, Australia
Research Site
Box Hill, Australia
Research Site
Clayton, Australia
Research Site
Greenslopes, Australia
Research Site
Herston, Australia
Research Site
Macquarie University, Australia
Research Site
Melbourne, Australia
Research Site
Nedlands, Australia
Research Site
Randwick, Australia
Research Site
Waratah, Australia

Austria

Research Site
Graz, Austria
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria

Brazil

Research Site
Barretos, Brazil
Research Site
Belo Horizonte, Brazil
Research Site
Curitiba, Brazil
Research Site
Florianópolis, Brazil
Research Site
Passo Fundo, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Recife, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Santo André, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Canada

Research Site
Edmonton, Alberta, Canada
Research Site
Kelowna, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Oakville, Ontario, Canada

164 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Feb 2017
Primary completion: 4 Jun 2019
Completion: 15 Feb 2023
Last update posted: 6 Oct 2023
Registered enrollment: 387
Registry id: NCT02987543

Cross-registrations

EU-CTR / CTIS (EudraCT)2016-000300-28

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.